Skip to main content
. 2019 Mar 27;63(4):e01814-18. doi: 10.1128/AAC.01814-18

TABLE 1.

In vitro activities of ceftazidime-avibactam and comparator antimicrobial agents tested against Enterobacteriaceae and P. aeruginosa isolatesa

Organism, phenotype/genotype (no. of isolates)b Antimicrobial agent MIC (μg/ml)
 % Susceptiblec
MIC50 MIC90 Range
Enterobacteriaceae (7,665) Ceftazidime-avibactam 0.12 0.5 ≤0.015 to >128 99.7
Ceftazidime 0.25 64 ≤0.015 to >128 69.9
Cefepime ≤0.12 >16 ≤0.12 to >16 70.4
Aztreonam 0.12 128 ≤0.015 to >128 68.0
Piperacillin-tazobactam 4 >128 ≤0.25 to >128 81.1
Doripenem 0.06 0.25 ≤0.008 to >4 95.5
Imipenem 0.25 2 ≤0.03 to >8 83.9
Meropenem 0.03 0.12 ≤0.004 to >8 94.9
Amikacin 2 8 ≤0.25 to >32 94.9
Colistin (n = 4,516)d 0.5 >4 ≤0.12 to >4 83.0
Tigecycline 0.5 2 ≤0.015 to >8 93.7
Levofloxacin 0.25 >4 ≤0.03 to >4 67.5
Enterobacteriaceae, MBL negative (7,648) Ceftazidime-avibactam 0.12 0.5 ≤0.015 to >128 99.9
Ceftazidime 0.25 64 ≤0.015 to >128 70.0
Cefepime ≤0.12 >16 ≤0.12 to >16 70.5
Aztreonam 0.12 128 ≤0.015 to >128 68.0
Piperacillin-tazobactam 4 128 ≤0.25 to >128 81.3
Doripenem 0.06 0.25 ≤0.008 to >4 95.7
Imipenem 0.25 2 ≤0.03 to >8 84.1
Meropenem 0.03 0.12 ≤0.004 to >8 95.1
Amikacin 2 8 ≤0.25 to >32 95.0
Colistin (n = 4,500)d 0.5 >4 ≤0.12 to >4 83.1
Tigecycline 0.5 2 ≤0.015 to >8 93.8
Levofloxacin 0.25 >4 ≤0.03 to >4 67.6
Escherichia coli (2,705) Ceftazidime-avibactam 0.12 0.25 ≤0.015 to 32 99.9
Ceftazidime 0.25 64 ≤0.015 to >128 70.9
Cefepime ≤0.12 >16 ≤0.12 to >16 67.7
Aztreonam 0.12 64 ≤0.015 to >128 67.7
Piperacillin-tazobactam 2 32 ≤0.25 to >128 88.9
Doripenem 0.03 0.06 ≤0.008 to >4 99.5
Imipenem 0.12 0.25 ≤0.03 to >8 99.2
Meropenem 0.03 0.06 ≤0.004 to >8 99.4
Amikacin 4 8 0.5 to >32 97.1
Colistin (n = 1,515)d 0.5 1 ≤0.12 to >4 99.5
Tigecycline 0.25 0.5 ≤0.015 to 4 99.9
Levofloxacin 1 >4 ≤0.03 to >4 51.9
Escherichia coli, MBL negative (2,703) Ceftazidime-avibactam 0.12 0.25 ≤0.015 to 8 100
Ceftazidime 0.25 64 ≤0.015 to >128 71.0
Cefepime ≤0.12 >16 ≤0.12 to >16 67.8
Aztreonam 0.12 64 ≤0.015 to >128 67.7
Piperacillin-tazobactam 2 32 ≤0.25 to >128 89.0
Doripenem 0.03 0.06 ≤0.008 to >4 99.6
Imipenem 0.12 0.25 ≤0.03 to >8 99.2
Meropenem 0.03 0.06 ≤0.004 to >8 99.5
Amikacin 4 8 0.5 to >32 97.1
Colistin (n = 1,513)d 0.5 1 ≤0.12 to >4 99.5
Tigecycline 0.25 0.5 ≤0.015 to 4 99.9
Levofloxacin 1 >4 ≤0.03 to >4 51.9
Klebsiella pneumoniae (2,128) Ceftazidime-avibactam 0.25 1 ≤0.015 to >128 99.5
Ceftazidime 2 128 ≤0.015 to >128 52.9
Cefepime 1 >16 ≤0.12 to >16 54.5
Aztreonam 1 >128 ≤0.015 to >128 51.9
Piperacillin-tazobactam 8 >128 ≤0.25 to >128 63.3
Doripenem 0.06 2 ≤0.008 to >4 86.7
Imipenem 0.25 4 0.06 to >8 87.8
Meropenem 0.06 4 0.008 to >8 84.7
Amikacin 2 16 ≤0.25 to >32 90.7
Colistin (n = 1,347)d 1 1 0.25 to >4 93.9
Tigecycline 0.5 2 0.06 to >8 96.4
Levofloxacin 0.5 >4 ≤0.03 to >4 64.9
Klebsiella pneumoniae, MBL negative (2,119) Ceftazidime-avibactam 0.12 1 ≤0.015 to >128 100
Ceftazidime 1 128 ≤0.015 to >128 53.1
Cefepime 0.5 >16 ≤0.12 to >16 54.7
Aztreonam 1 >128 ≤0.015 to >128 52.0
Piperacillin-tazobactam 8 >128 ≤0.25 to >128 63.5
Doripenem 0.06 2 ≤0.008 to >4 87.0
Imipenem 0.25 4 0.06 to >8 88.2
Meropenem 0.06 4 0.008 to >8 85.0
Amikacin 2 16 ≤0.25 to >32 90.9
Colistin (n = 1,338)d 1 1 0.25 to >4 94.2
Tigecycline 0.5 2 0.06 to >8 96.5
Levofloxacin 0.5 >4 ≤0.03 to >4 64.9
Klebsiella oxytoca (393)e Ceftazidime-avibactam 0.12 0.25 ≤0.015 to 16 99.8
Ceftazidime 0.12 8 0.03 to >128 89.6
Cefepime ≤0.12 4 ≤0.12 to >16 88.0
Aztreonam 0.12 64 ≤0.015 to >128 81.9
Piperacillin-tazobactam 2 128 ≤0.25 to >128 86.5
Doripenem 0.06 0.12 0.03 to >4 98.5
Imipenem 0.25 0.5 0.06 to >8 96.7
Meropenem 0.03 0.06 0.015 to >8 98.0
Amikacin 2 4 0.5 to >32 98.2
Colistin (n = 239)d 0.5 1 ≤0.12 to 4 99.2
Tigecycline 0.25 1 0.06 to 4 99.8
Levofloxacin 0.06 1 ≤0.03 to >4 93.4
Enterobacter spp. (855)f Ceftazidime-avibactam 0.25 1 ≤0.015 to 128 99.2
Ceftazidime 0.5 128 0.03 to >128 66.7
Cefepime ≤0.12 >16 ≤0.12 to >16 78.2
Aztreonam 0.12 128 ≤0.015 to >128 66.2
Piperacillin-tazobactam 4 >128 ≤0.25 to >128 75.6
Doripenem 0.06 0.25 ≤0.008 to >4 97.3
Imipenem 0.5 2 ≤0.03 to >8 83.4
Meropenem 0.06 0.12 0.008 to >8 97.3
Amikacin 2 8 ≤0.25 to >32 96.1
Colistin (n = 496)d 0.5 1 ≤0.12 to >4 93.5
Tigecycline 0.5 1 0.06 to 8 97.8
Levofloxacin 0.06 >4 ≤0.03 to >4 86.4
Enterobacter spp., MBL negative (851) Ceftazidime-avibactam 0.25 1 ≤0.015 to 32 99.5
Ceftazidime 0.5 128 0.03 to >128 66.9
Cefepime ≤0.12 >16 ≤0.12 to >16 78.5
Aztreonam 0.12 128 ≤0.015 to >128 66.0
Piperacillin-tazobactam 4 >128 ≤0.25 to >128 75.8
Doripenem 0.06 0.25 ≤0.008 to >4 97.8
Imipenem 0.5 2 ≤0.03 to >8 83.8
Meropenem 0.06 0.12 0.008 to >8 97.6
Amikacin 2 8 ≤0.25 to >32 96.2
Colistin (n = 493)d 0.5 1 ≤0.12 to >4 93.5
Tigecycline 0.5 1 0.06 to 8 97.8
Levofloxacin 0.06 >4 ≤0.03 to >4 86.4
Citrobacter spp. (394)g Ceftazidime-avibactam 0.12 0.5 ≤0.015 to 128 99.5
Ceftazidime 0.5 128 ≤0.015 to >128 74.6
Cefepime ≤0.12 8 ≤0.12 to >16 86.3
Aztreonam 0.12 64 ≤0.015 to >128 72.3
Piperacillin-tazobactam 4 64 0.5 to >128 81.5
Doripenem 0.06 0.12 0.015 to >4 98.7
Imipenem 0.5 2 0.06 to >8 88.1
Meropenem 0.03 0.06 ≤0.004 to >8 98.0
Amikacin 2 4 ≤0.25 to >32 94.9
Colistin (n = 237)d 0.5 1 ≤0.12 to 2 100
Tigecycline 0.25 1 0.06 to 4 99.5
Levofloxacin 0.06 >4 ≤0.03 to >4 86.8
Citrobacter spp., MBL negative (393) Ceftazidime-avibactam 0.12 0.5 ≤0.015 to 128 99.8
Ceftazidime 0.5 128 ≤0.015 to >128 74.8
Cefepime ≤0.12 8 ≤0.12 to >16 86.5
Aztreonam 0.12 64 ≤0.015 to >128 72.5
Piperacillin-tazobactam 4 64 0.5 to >128 81.7
Doripenem 0.06 0.12 0.015 to >4 99.0
Imipenem 0.5 2 0.06 to >8 88.3
Meropenem 0.03 0.06 ≤0.004 to >8 98.2
Amikacin 2 4 ≤0.25 to >32 94.9
Colistin (n = 236)d 0.5 1 ≤0.12 to 2 100
Tigecycline 0.25 1 0.06 to 4 99.5
Levofloxacin 0.06 >4 ≤0.03 to >4 87.0
Proteeae (939)h Ceftazidime-avibactam 0.06 0.12 ≤0.015 to 64 99.9
Ceftazidime 0.06 4 ≤0.015 to >128 93.6
Cefepime ≤0.12 8 ≤0.12 to >16 88.2
Aztreonam ≤0.015 1 ≤0.015 to >128 95.0
Piperacillin-tazobactam 0.5 2 ≤0.25 to >128 98.5
Doripenem 0.25 0.5 0.015 to >4 98.8
Imipenem 2 4 0.06 to >8 23.2
Meropenem 0.12 0.25 0.03 to 8 99.8
Amikacin 4 8 ≤0.25 to >32 96.3
Colistin (n = 532)d >4 >4 0.5 to >4 0.8
Tigecycline 2 4 ≤0.015 to >8 60.9
Levofloxacin 0.12 >4 ≤0.03 to >4 75.4
Proteeae, MBL negative (938) Ceftazidime-avibactam 0.06 0.12 ≤0.015 to 8 100
Ceftazidime 0.06 2 ≤0.015 to >128 93.7
Cefepime ≤0.12 4 ≤0.12 to >16 88.3
Aztreonam ≤0.015 1 ≤0.015 to >128 95.0
Piperacillin-tazobactam 0.5 2 ≤0.25 to >128 98.6
Doripenem 0.25 0.5 0.015 to 4 98.9
Imipenem 2 4 0.06 to >8 23.2
Meropenem 0.12 0.12 0.03 to 2 99.9
Amikacin 4 8 ≤0.25 to >32 96.3
Colistin (n = 531)d >4 >4 0.5 to >4 0.8
Tigecycline 2 4 ≤0.015 to >8 61.0
Levofloxacin 0.12 >4 ≤0.03 to >4 75.4
Other Enterobacteriaceae (251)e,i Ceftazidime-avibactam 0.25 0.5 ≤0.015 to >128 99.6
Ceftazidime 0.25 16 0.03 to >128 86.0
Cefepime ≤0.12 16 ≤0.12 to >16 87.2
Aztreonam 0.12 64 0.03 to >128 84.0
Piperacillin-tazobactam 2 16 ≤0.25 to >128 92.8
Doripenem 0.12 0.25 0.03 to >4 98.0
Imipenem 0.5 1 0.06 to >8 90.0
Meropenem 0.06 0.12 0.03 to >8 98.0
Amikacin 2 8 ≤0.25 to >32 92.4
Colistin (n = 150)d >4 >4 ≤0.12 to >4 23.3
Tigecycline 1 2 0.06 to 8 95.2
Levofloxacin 0.12 2 ≤0.03 to >4 93.6
Pseudomonas aeruginosa (1,794) Ceftazidime-avibactam 2 16 0.12 to >128 87.4
Ceftazidime 4 64 0.25 to >128 70.0
Cefepime 4 >16 ≤0.12 to >16 73.0
Aztreonam 8 64 0.12 to >128 55.9
Piperacillin-tazobactam 8 >128 ≤0.25 to >128 62.5
Doripenem 1 >4 ≤0.015 to >4 66.0
Imipenem 2 >8 0.12 to >8 56.9
Meropenem 1 >8 0.03 to >8 64.2
Amikacin 4 >32 ≤0.25 to >32 81.6
Colistin (n = 1,301)d 2 2 0.25 to >8 94.9
Levofloxacin 1 >4 ≤0.03 to >4 65.7
Pseudomonas aeruginosa, MBL negative (1,684) Ceftazidime-avibactam 2 8 0.12 to >128 92.8
Ceftazidime 4 64 0.25 to >128 74.4
Cefepime 4 >16 ≤0.12 to >16 77.1
Aztreonam 8 64 0.12 to >128 58.1
Piperacillin-tazobactam 8 >128 ≤0.25 to >128 66.1
Doripenem 1 >4 ≤0.015 to >4 70.1
Imipenem 2 >8 0.12 to >8 60.6
Meropenem 1 >8 0.03 to >8 68.1
Amikacin 4 >32 ≤0.25 to >32 86.1
Colistin (n = 1,213)d 2 2 0.25 to 8 94.8
Levofloxacin 1 >4 ≤0.03 to >4 69.1
a

Isolates of Enterobacteriaceae (n = 7,665) and P. aeruginosa (n = 1,794) were collected in the Latin American region as part of the INFORM global surveillance program in 2012 to 2015.

b

MBL negative; no gene encoding a metallo-β-lactamase was detected by PCR assay.

c

Percent susceptibility was determined according to CLSI 2016 breakpoints, with the exception of those for ceftazidime-avibactam and tigecycline, where U.S. FDA breakpoints were applied, and for colistin, where EUCAST breakpoints were applied.

d

Values are for colistin tested without 0.002% polysorbate-80; isolates collected in 2014 to 2015 only.

e

All isolates were MBL negative.

f

Enterobacter spp. included Enterobacter aerogenes (n = 272), Enterobacter amnigenus (n = 1), Enterobacter asburiae (n = 48), Enterobacter cloacae (n = 512), Enterobacter kobei (n = 18), and Enterobacter ludwigii (n = 4).

g

Citrobacter spp. included Citrobacter amalonaticus (n = 5), Citrobacter braakii (n = 19), Citrobacter farmeri (n = 1), Citrobacter freundii (n = 274), and Citrobacter koseri (n = 95).

h

Proteeae included Morganella morganii (n = 213), Proteus mirabilis (n = 496), Proteus penneri (n = 13), Proteus vulgaris (n = 152), Providencia alcalifaciens (n = 2), Providencia rettgeri (n = 29), and Providencia stuartii (n = 34).

i

Other Enterobacteriaceae included Escherichia vulneris (n = 1), Klebsiella variicola (n = 1), Kluyvera ascorbata (n = 1), Pantoea agglomerans (n = 1), Pluralibacter gergoviae (n = 2), Raoultella ornithinolytica (n = 33), Raoultella planticola (n = 1), Serratia liquefaciens (n = 2), Serratia marcescens (n = 206), and Serratia ureilytica (n = 3).